Clinical Development Pipeline. Research & Development. Genetic Medicines. Principles of Medical Research. 100 Years of Insulin. DISEASE AREAS. Alzheimer's.

14 июл. 2023 г. · Combining incretins with bimagrumab “has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes ...

14 июл. 2023 г. · The pharmaceutical company will pay up to $1.9 billion to acquire the privately held biotech and its experimental antibody.

14 июл. 2023 г. · Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling.

Executive Summary. Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity.

14 июл. 2023 г. · The Versanis acquisition will bolster Lilly's existing weight-loss drug pipeline, which includes Mounjaro (tirzepatide), which has a similar ...

14 июл. 2023 г. · Eli Lilly reached a deal to buy Versanis Bio, a privately held biotech which is testing a monoclonal antibody drug called bimagrumab as a ...

14 июл. 2023 г. · Versanis is developing a monoclonal antibody called bimagrumab that is being studied alone and in combination with the popular weight-loss drug ...

17 июл. 2023 г. · This acquisition adds a completely new weight loss mechanism to Lilly's portfolio, although Lilly seems more focused on “the potential of ...

Of Versanis' pipeline in development, Bimagrumab is also the most talked about is a monoclonal antibody drug that acts directly on fat cells and is able to ...